Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects

Hepatology. 2013 Mar;57(3):903-7. doi: 10.1002/hep.25843. Epub 2013 Jan 29.
No abstract available

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic / methods
  • Drug Approval / methods*
  • Drug Monitoring / methods*
  • Drug Resistance, Viral
  • Drug Therapy, Combination / standards
  • Evidence-Based Medicine / methods
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon-alpha / therapeutic use
  • Proline / administration & dosage
  • Proline / analogs & derivatives*
  • Proline / therapeutic use
  • Ribavirin / therapeutic use
  • United States

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Ribavirin
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline